PTGS2 and peptic ulcer disease: Given that not all NSAID users develop peptic ulcers during treatment, this study specifically recruited individuals at elevated risk, including those with a history of endoscopically confirmed peptic ulcers and a need for continuous, long-term NSAID therapy (inclusive of selective cyclooxygenase-2 inhibitors) for pain management purposes.